Clinical trials: Vaginal Yeast Infections
Vulvovaginal Candidiasis
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
This is a multi-center, randomized, double-blind, placebo-controlled study intended to assess the safety, tolerability and humoral and cellular immune response over a 12-month period after receiving one dose of either the NDV-3A…
- Trial name
- NCT01926028
- Testing
- NDV-3A, NDV-3
- Where
- 20 sites in United States
- Volunteers
- 188 people
- Sponsor
- NovaDigm Therapeutics, Inc.
Bacterial Vaginosis, Candida Albicans Vulvovaginitis
Evaluation of a Rapid Microscopic Diagnostic System for Different Vaginitis Conditions
Evaluate the diagnostic performance of the Gyni™ device to detect different vaginitis conditions by comparison to microscopic diagnosis and related lab tests.
- Conditions
- Bacterial Vaginosis, Candida Albicans Vulvovaginitis, Candida Vulvovaginitis, Trichomonas Vaginitis
- Trial name
- NCT04219605
- Where
- Israel
- Volunteers
- 226 people
- Sponsor
- Meir Medical Center
Infection, Bacterial, Infection, Fungal
Point-of-care Tests for Bacterial Vaginosis and Candidosis
Vaginal infection in early pregnancy is associated with an increased risk of spontaneous preterm delivery and late miscarriage. Most studies presume that vaginal infections are responsible for up to 40% of preterm birth.
- Conditions
- Infection, Bacterial, Infection, Fungal, Preterm Birth
- Trial name
- NCT04287504
- Testing
- SavvyCheck Vaginal Yeast Test, OSOM BVBLUE Test
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Microbiome, Antibiotic-Induced VVC
Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women
Background: Vaginal yeast infections are caused by a fungus called Candida. Candida can live harmlessly in the vagina, but most women will have symptoms from a vaginal yeast infection at some point during their life.
- Conditions
- Microbiome, Antibiotic-Induced VVC, Vaginal Candidiasis
- Trial name
- NCT01915251
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bacterial Vaginosis, Fungal Vaginal Infections
Clinical Protocol CERN Feasibility Study
The goal of this clinical trial is to learn if the intravaginal Cern device works to treat bacterial vaginosis and fungal vaginitis in premenopausal women. It will also learn about the safety of the device.
- Trial name
- NCT06933420
- Testing
- Cern Device
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cern Corporation
Bacterial Vaginosis, Vulvovaginal Candidiasis
Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection
The purpose of this clinical trial is to investigate the clinical efficacy and safety of a Live Biotherapeutic Product (BGY-1601-VT) intended as a first line of treatment in cases of acute vaginal infection without upfront…
- Trial name
- ELINA (NCT06450990)
- Testing
- BGY-1601-VT
- Volunteers
- 165 people
- Sponsor
- NEXBIOME THERAPEUTICS
Vaginitis, Bacterial Vaginosis
Point of Care Diagnosis of Vaginal Infections
Vaginal infections are a common gynecologic issue and may cause significant symptoms and discomfort for individuals. Point of care tests are used to diagnose infections in the office, with an advantage of quick diagnosis and…
- Conditions
- Vaginitis, Bacterial Vaginosis, Yeast Vaginitis, Trichomonas Vaginitis
- Trial name
- PAT (NCT06438575)
- Testing
- Xpert® Xpress MVP test, Usual Care
- Where
- United States
- Volunteers
- 351 people
- Sponsor
- Sharon L Hillier
Recurrent Vulvovaginal Candidiasis
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
Pevion Biotech develops a state-of-the-art vaccine against recurrent vulvovaginal candidiasis (RVVC) caused by the pathogenic form of Candida albicans especially in pre-menopausal women of childbearing age with a history of…
- Trial name
- NCT01067131
- Testing
- PEV7C1, PEV7C9, PEV7B2
- Where
- 2 sites in Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pevion Biotech Ltd
Recurrent Vulvovaginal Candidiasis
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older…
- Trial name
- CANDLE (NCT04029116)
- Testing
- Fluconazole Tablet, IBREXAFUNGERP
- Where
- 25 sites in United States
- Volunteers
- 440 people
- Sponsor
- Scynexis, Inc.
Vaginal Infection, ASC-US
Probiotic Implementation as Help in Solving Vaginal Infections
Over recent years, a growing interest has developed in microbiota and in the concept of maintaining a special balance between Lactobacillus and other bacteria species in order to promote women's well-being.
- Trial name
- NCT03372395
- Testing
- Lactobacillus rhamnosus BMX 54
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Vulvovaginal Candidiasis, Candida Infection
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply…
- Conditions
- Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
- Trial name
- NCT06954493
- Testing
- Ibrexafungerp
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.
- Trial name
- NCT05399641
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 150 people
- Sponsor
- Scynexis, Inc.
Bacterial Vaginosis
Suppression Of Bacterial Vaginosis (BV) [SUBVert]
A Phase II randomized, double-blind, placebo-controlled study screening approximately 600 adult females, aged 18-55, with a goal to enroll approximately 250 participants to achieve 200 evaluable participants at the test of cure…
- Trial name
- NCT03930745
- Testing
- TOL-463
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vulvovaginal Candidiases, Yeast Infection
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
- Conditions
- Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal
- Trial name
- NCT03167957
- Testing
- Oral Encochleated Amphotericin B (CAMB)
- Where
- United States
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Candidiasis, Vulvovaginal
Vulvovaginal Candidiasis in Canadian Females
Vulvovaginal candidiasis (VVC; colloquially referred to as a 'yeast infection') is a prevalent mucosal infection caused by Candida spp. that affects ~75% of women at least once in their life.
- Trial name
- THRIVE-yeast (NCT04930107)
- Testing
- Fluconazole 150 mg, Boric Acid Supp,Vag
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Manitoba